Hormone Replacement Therapy and Risk of Endometrial Cancer: Results from a Prospective cohort study
Principal Investigator
Name
Hao Liu
Degrees
Ph.D
Institution
Guangdong Food and Drug Vocational College, Guangzhou, Guangdong, China
Position Title
Dr.
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-734
Initial CDAS Request Approval
Feb 17, 2021
Title
Hormone Replacement Therapy and Risk of Endometrial Cancer: Results from a Prospective cohort study
Summary
Hormone replacement therapy (HRT) is an appropriate treatment for women with the climacteric syndrome. The estrogen component of HRT electively alleviates climacteric symptoms but also stimulates the endometrium and thus may increase the risk of endometrial cancer (EC). However, this relationship is controversial. For example, the continuous, daily use of a synthetic progestin in combination with estradiol over the course of 5 years has been shown to significantly reduce the risk of EC in the Women’s Health Initiative (WHI) trial [1]. Whereas the continuous daily use of a synthetic progestin decreases the risk of EC, the long-term use of a synthetic progestin in a sequential (non-daily) combination with estradiol has been shown to increase the risk of EC in some, but not in other studies [2]. Therefore, there is need to assess the relationship more precisely.
1. Chlebowski, R.T.; Anderson, G.L.; Sarto, G.E.; Haque, R.; Runowicz, C.D.; Aragaki, A.K.; Thomson, C.A.; Howard, B.V.; Wactawski-Wende, J.; Chen, C.; et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women’s Health Initiative Randomized Trial. J. Natl. Cancer Inst. 2016, 108.
[CrossRef]
2. Razavi, P.; Pike, M.C.; Horn-Ross, P.L.; Templeman, C.; Bernstein, L.; Ursin, G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol. Biomark. Prev. 2010, 19, 475–483. [CrossRef]
1. Chlebowski, R.T.; Anderson, G.L.; Sarto, G.E.; Haque, R.; Runowicz, C.D.; Aragaki, A.K.; Thomson, C.A.; Howard, B.V.; Wactawski-Wende, J.; Chen, C.; et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women’s Health Initiative Randomized Trial. J. Natl. Cancer Inst. 2016, 108.
[CrossRef]
2. Razavi, P.; Pike, M.C.; Horn-Ross, P.L.; Templeman, C.; Bernstein, L.; Ursin, G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol. Biomark. Prev. 2010, 19, 475–483. [CrossRef]
Aims
To examine the association between HRT use and endometrial cancer incidence using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial prospective cohort.
Collaborators
NA